Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

ABSTRACT:

Background

The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.

Methods

Of 2057 eligible patients, 1155 were allocated to augmented arms in which PEG ASNase replaced native ASNase postinduction. Erwinia chrysanthemi (Erwinia) ASNase could be used to replace native ASNase after allergy, if available. Allergy and survival data were complete for 990 patients. End-induction antibody titers were available for 600 patients.

Results

During the consolidation phase, 289 of 990 patients (29.2%) had an allergic reaction. The

SUBMITTER: Ko RH 

PROVIDER: S-EPMC4795901 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature